Literature DB >> 29560652

Sorafenib induced hepatic encephalopathy.

S S Sidhu1, S Agarwal1, O Goyal1, H Kishore1, S Sidhu2.   

Abstract

A 60 year old male, known case of Hepatitis C related cirrhosis was diagnosed with exophytic Hepatocellular carcinoma (size 2.1 x 2.2 cm), Barcelona Clinic Liver Cancer Stage A, on routine surveillance. He refused liver Transplant and underwent laparoscopic segmental resection. Thereafter patient was started on Tablet Sorafenib 400mg twice daily to prevent recurrence of Hepatocellular carcinoma. On 18st post-operative day, patient presented with Hepatic encephalopathy. Routine investigations and MRI Brain were normal; Venous ammonia was high. Sorafenib was discontinued, and neurological symptoms resolved within 24 hours. The ammonia level decreased from 112 to 30 μmol/L. Hepatic encephalopathy recurred 14 days after Sorafenib reintroduction at a dose of 400 mg / day. It resolved within 24 hours of withdrawal of Sorafenib. Sorafenib induced recurrent acute overt Hepatic encephalopathy with biochemical corroboration is reported here. © Acta Gastro-Enterologica Belgica.

Entities:  

Keywords:  Sorafenib; hepatic encephalopathy; hepatocellular carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29560652

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  1 in total

1.  Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway.

Authors:  Can-Can Zhou; Yu-Qiong He; Yu-Shuang Qiu; Chen-Xu Ni; Fu-Ming Shen; Dong-Jie Li
Journal:  Biol Trace Elem Res       Date:  2022-02-07       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.